Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nimotuzumab combined with NALIRIFOX for locally advanced pancreatic cancer
ChiCTR2400084660Phase 2Not yet recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- May 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nimotuzumab in pancreatic cancer (PC) and pancreatic adenocarcinoma (PDAC), sponsored by Peking Union Medical College Hospital. Primary endpoint: Overall survival. Planned start May 2024; status: not yet recruiting.
02
Drugs
nimotuzumab
03
Conditions
pancreatic cancer (PC)pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on ChiCTR2400084660.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400084660.